No Data
REMEGEN(9995.HK):STRONG SALES IN Q3 WITH A NARROWED NET LOSS
The Hong Kong stock sector generally fell with trading volume increasing to 160 billion Hong Kong dollars. Institutions believe that the Hang Seng Index at 19,500 points is worth absorbing.
Produced jointly by Zhongtai International and CaiLian News.
REMEGEN CO. LTD.(09995.HK):CONTINUOUS IMPROVEMENT OF FINANCIAL PERFORMANCE
Hong Kong Stock Market Moves | Remegen (09995) rose by more than 10%, with a significant increase in the company's main business income. The third-quarter loss narrowed by more than 30% compared to the previous quarter.
Remegen (09995) rose more than 10%, as of the time of publication, increased by 10.8%, to 16 Hong Kong dollars, with a turnover of 78.6233 million Hong Kong dollars.
Hong Kong stocks are active | Some pharmaceutical stocks rose in early trading, as the national medical insurance negotiations are expected to start soon. Institutions stated that there will be a high concentration of catalytic events in the sector in the
Some pharmaceutical stocks rose in the morning session. As of the time of publication, Remegen (09995) rose by 8.73% to HKD 15.7; SciClone Pharmaceuticals-B (02171) rose by 6.47% to HKD 15.7; Sino Biopharmaceutical-B (01952) rose by 2.11% to HKD 31.5; Fosun Pharma (02196) rose by 3.7% to HKD 15.12.
RemeGen Posts Loss in Q3; Shanghai Shares Rise 4%
No Data
No Data